Phillygenin-O-β-glucosaminide
Phillygenin-O-β-glucosaminide is an orally active Nrf2 inducer and NF-κB inhibitor that inhibits osteoclast differentiation and ROS production by promoting Nrf2 nuclear translocation, suppressing NF-κB and JNK phosphorylation, and downregulating NFATc1, c-Fos, MMP9, and CTSK expression. Phillygenin-O-β-glucosaminide can be used for research on osteoarthritis.
For research use only. We do not sell to patients.
- Formula: C27H35NO10
- Molecular Weight:533.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
Nrf2 |
NF-κB |
JNK |
MMP9 |
NFATc1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | EC50 |
390.6 μM
|
Cytotoxicity against murine RAW264.7 cells assessed as reduction in cell viability incubated for 96 hrs.
Cytotoxicity against murine RAW264.7 cells assessed as reduction in cell viability incubated for 96 hrs.
|
42561561 |
| RAW264.7 | IC50 |
82.02 μM
|
Inhibition of RANKL and M-CSF-induced osteoclast differentiation in murine RAW264.7 cells.
Inhibition of RANKL and M-CSF-induced osteoclast differentiation in murine RAW264.7 cells.
|
42561561 |
In Vitro
Phillygenin-O-β-glucosaminide (50-200 μM) inhibits RANKL- and M-CSF-induced osteoclast differentiation in RAW264.7 cells with an IC50 of 82.02 μM[1].
Phillygenin-O-β-glucosaminide (1 μM) exhibits moderate plasma protein binding in human plasma[1].
Phillygenin-O-β-glucosaminide (45 min) is metabolically stable in human liver microsomes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SW1353 human chondrosarcoma cells
-
Concentration:50, 100, 200, 400, 800 μM
-
Incubation Time:24 h
-
Result:Exhibited dose-dependent anti-inflammatory activity.
-
Cell Line:RAW264.7 murine macrophage cells
-
Concentration:50, 100, 200, 400, 800 μM
-
Incubation Time:96 h
-
Result:Exhibited dose-dependent anti-osteoclast formation activity.
-
Cell Line:IL-1β-induced SW1353 human chondrosarcoma cells
-
Concentration:200, 400, 800 μM
-
Incubation Time:24 h
-
Result:Concentration-dependently upregulated the expression of collagen II and downregulated the expression of MMP13.
Markedly upregulated the expression of Nrf2 and HO-1, and downregulated the expression of p-JNK.
-
Cell Line:IL-1β-stimulated SW1353 human chondrosarcoma cells
-
Concentration:200, 400, 800 μM
-
Incubation Time:24 h
-
Result:Increased the nuclear-to-cytoplasmic ratio of Nrf2 fluorescence intensity in a concentration-dependent manner.
-
Cell Line:RAW264.7 murine macrophage cells
-
Concentration:50, 100, 200 μM
-
Incubation Time:4 days
-
Result:Concentration-dependently downregulated the expression of core osteoclast differentiation-related proteins, including NFATc1, c-Fos, MMP9, and CTSK.
Suppressed NF-κB pathway activation, as evidenced by reduced p-p65/p65 ratio and cleaved IL-1β levels.
-
Cell Line:RAW264.7 cells
-
Concentration:50, 100, 200, 400, 800 μM
-
Incubation Time:96 h
-
Result:Determined the EC50 value to be 390.6 μM.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (male, 8 weeks old)[1]
-
Dosage:50, 100, 200 mg/kg
-
Administration:i.g.; once daily; 30 consecutive days
-
Result:Improved grip strength in a dose-dependent manner.
Significantly improved grip strength compared to the combination group at 100 mg/kg.
Showed effects superior to diacerein groups at 200 mg/kg.
Significantly restored the mechanical pain threshold and outperformed phillyrin and the phillyrin-glucosamine combination in analgesic efficacy at 200 mg/kg.
Dose-dependently alleviated cartilage structural damage and inhibited matrix degradation, with efficacy comparable to the DIA-M group at 200 mg/kg.
Significantly reduced inflammatory cell infiltration and IL-6 levels compared to phillyrin and the combination group at 100 mg/kg.
Showed anti-inflammatory efficacy comparable to the DIA-M group at 200 mg/kg.
Dose-dependently inhibited osteoclast formation, with significantly fewer osteoclasts per site than phillyrin and the combination group at 100 mg/kg.
Significantly upregulated Nrf2 pathway proteins at 200 mg/kg.
Suppressed p-JNK at 100 mg/kg.
No significant toxicity was observed at doses up to 200 mg/kg for 30 days.
- Kinase activity and phosphorylation assays
- Cytoplasmic-Nuclear Fractionated Protein Extraction
- Western Blot
- RNA extraction experimental
- ROS/oxidative-stress fluorescent staining
- Research Protocol for Inflammation-related Diseases
- Protocol for Kinase activity and phosphorylation assays
- Osteoclast differentiation from monocyte/macrophage precursors
Chemical Information
-
Molecular Weight 533.57
-
Formula C27H35NO10
-
SMILES
COC1=CC=C([C@@H](OC[C@]23[H])[C@@]2(CO[C@H]3C(C=C4OC)=CC=C4O[C@H]5[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O5)[H])C=C1OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Phillygenin-O-β-glucosaminide Related Classifications
HY-189489 Related Classifications
Powered by Bioz